GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
|Slideshows|August 23, 2018
Psychiatry Rounds: Workplace Mental Health and More
Author(s)Laurie Martin
The perils of job insecurity; depression and cardiac risks; the longest-running mental health study; smart drugs that aren’t so smart; heatstroke in psychiatric patients; an autism puzzler; and psychosis and eating disorders.
Advertisement
Advertisement
Related to this article
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
Brain Trust: Bessel van der Kolk, MD, on Complex PTSD, Attachment, and the Limits of Pharmacotherapy
3
Podcast: Campus Naloxone Access and Destigmatizing Substance Use Disorders
4
Artificial Intelligence in Psychiatric Clinical Trials: Opportunities and Limitations
5